Address
Email address
https://parasym.coParasym™ | Neuromodulation for Better Health Parasym™ is your clinically proven wearable device designed to deliver innovative Neuromodulation. Certified and patented, Parasym modulates the vagus nerve to achieve therapeutic benefit.
Name
Parasym OÜ
Registry code
16114591
VAT number
EE102341670
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
04.12.2020 (3)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
74901 - Other professional, scientific and technical activities n.e.c.
1 077 172 €
742 956 €
69%
-
958 645 €
0
Submitted
No tax arrears
78%
77%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Nathan Andrew Dundovic 25.03.1993 (31) | 50% - 1 250.00 EUR | Board member | Direct ownership | Founder |
| Sophie Marie Dundovic 05.08.1991 (33) | 50% - 1 250.00 EUR | Board member | Direct ownership | Founder |
| B2baltics consulting OÜ 14104246 | - | Contact person | - |
| 2021 13.04.2023 | 2022 08.01.2024 | 2023 12.06.2024 | |
|---|---|---|---|
| Total Revenue | 37 955 € | 222 827 € | 1 077 172 € |
| Net profit (loss) for the period | 30 634 € | 185 055 € | 742 956 € |
| Profit Margin | 81% | 83% | 69% |
| Current Assets | 31 474 € | 227 372 € | 963 681 € |
| Fixed Assets | - | - | - |
| Total Assets | 31 474 € | 227 372 € | 963 681 € |
| Current Liabilities | 840 € | 11 683 € | 5 036 € |
| Non Current Liabilities | - | - | - |
| Total Liabilities | - | - | - |
| Share Capital | - | - | - |
| Equity | 30 634 € | 215 689 € | 958 645 € |
| Employees | 0 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 174 052.45 € | 223 € | - | - |
| 2023 Q4 | - | - | - | - |
| 2023 Q3 | 1 138.41 € | 227.68 € | - | - |
| 2023 Q2 | - | - | - | - |
| 2023 Q1 | - | - | - | - |
| 2022 Q4 | - | - | - | - |
| 2022 Q3 | - | - | - | - |
| 2022 Q2 | - | - | - | - |
| 2022 Q1 | - | - | - | - |
| 2021 Q4 | - | - | - | - |
| 2021 Q3 | - | - | - | - |
| 2021 Q2 | 12 000 € | - | - | - |
| 2021 Q1 | - | - | - | - |
